GlassScriptPhysician profile
Lilly Ann Stallmer
NPI 1457113052
$1,383.88
in general payments reported to CMS, 2019-2025
31 companies · $895 in 2025
The $895 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $489 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $278.37 | 2024-2025 | |
| Pfizer INC. | $111.40 | 2024-2025 | |
| Incyte Corporation | $96.48 | 2024-2025 | Jakafi |
| Shorla Oncology INC. | $71.20 | 2025 | |
| Merck Sharp & Dohme LLC | $64.80 | 2024-2025 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $58.56 | 2025 | Lynozyfic |
| Lilly USA, LLC | $53.96 | 2024-2025 | Retevmo, Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $46.90 | 2024 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $41.79 | 2024-2025 | |
| Beone Medicines USA, INC. | $41.63 | 2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $41.46 | 2024-2025 | Trodelvy |
| Springworks Therapeutics, INC. | $40.93 | 2024-2025 | Ogsiveo |
| Caris Mpi, INC. | $38.60 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $31.22 | 2025 | Xermelo |
| Agios Pharmaceuticals, INC. | $30.05 | 2025 | Pyrukynd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.07 | 2025 | Vyloy |
| Abbvie INC. | $28.99 | 2025 | |
| Karyopharm Therapeutics INC. | $25.83 | 2025 | Xpovio |
| Genzyme Corporation | $25.45 | 2025 | |
| Emd Serono, INC. | $24.33 | 2025 | |
| Pharmacosmos Therapeutics INC. | $22.22 | 2025 | Monoferric |
| Genentech USA, INC. | $20.44 | 2025 | Polivy |
| Exelixis INC. | $19.97 | 2024 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $19.84 | 2025 | |
| Tempus Ai, INC | $18.97 | 2024 | Xt Cdx |
| Sobi, INC | $18.46 | 2024 | |
| Rigel Pharmaceuticals, INC. | $18.32 | 2024 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $17.46 | 2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $16.48 | 2024 | |
| Pharmaessentia USA Corporation | $16.30 | 2024 | Besremi |
| Eisai INC. | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly Stallmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.